News

The trial was a pivotal Phase 2/3 study designed to evaluate KEYTRUDA compared to chemotherapy based on prospective measurement of PD-L1 expression in previously treated patients with advanced

"CDI results from damage to the microbiome, and patients experience further collateral damage through the use of broad spectrum antibiotics to treat CDI, leaving them vulnerable to recurrent

The Company also announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with Systemic Lupus Erythematosus (SLE). "We are advancing XmAb5871 in IgG4-RD

The agreement covers the compound BI655066, an anti-IL-23 monoclonal biologic antibody in Phase 3 development for psoriasis. BI 655066 selectively blocks IL-23, a key protein involved in skin

Rintega (rindopepimut) is an investigational immunotherapy that targets the tumor specific oncogene EGFRvIII, a functional and permanently activated mutation of the epidermal growth factor receptor (EGFR) which has

Two doses of the drug were tested against a placebo and an oral antiviral called ribavarin to evaluate their effect on survival of immune-deficient mice infected with Zika

The companies have signed an agreement in which Bristol-Myers Squibb has become a LabCentral platinum sponsor. As part of the agreement, Bristol-Myers Squibb can nominate up to two

The approval is based on data from the Phase 3 RESONATE-2 (PCYC-1115) study, the first head-to-head clinical trial comparing IMBRUVICA to a chemotherapy agent. Results showed IMBRUVICA significantly

Detailed results of this combined analysis of UNCOVER-2 and UNCOVER-3 were presented during the American Academy of Dermatology (AAD) Annual Meeting taking place March 4-8 in Washington, D.C.